New Innovative treatment for patients with moderate-to-severe Atopic Dermatitis &  severe Asthma

Egypt is the 1st country in Africa approved Dupixent for moderate-to- severe Atopic Dermatitis & severe Asthma

  

  • Dupixent included in Egypt' s list approved drugs that meet urgent clinical need is the only biologic medicine approved for atopic dermatitis in Africa
  • Dupixent is approved in more than 60 countries with approximately 300,000 patients on therapy 

Cairo Egypt: Sanofi Egypt launched its latest medicine Dupixent® (dupilumab) at a press conference held on Sunday, August 1st. The Egyptian Drug Authority - EDA  in Egypt  has approved last April Dupixent® (dupilumab), for use in adults & adolescents 12 years and older  for 2 chronic diseases :

  • As a treatment of moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
  • As an add-on maintenance treatment for severe asthma with type 2 inflammation.

Atopic dermatitis is a chronic inflammatory disease that often appears as a rash on the skin. Moderate-to-severe atopic dermatitis is characterized by rashes that can potentially cover much of the body, and can include intense, persistent itching, skin dryness and skin lesions including cracking, redness or darkness, crusting and oozing. Itch is one of the most burdensome symptoms for patients and can be debilitating. Inadequately controlled atopic dermatitis can have a physical, emotional and psychosocial impact, causing sleep disturbance, symptoms of anxiety and depression, and feelings of isolation.

“According to recent research, AD affected worldwide 171 million people on 2019(8). 15-20% of children (9) and 1-3% of adults, said Professor Dr. Assem Farag – Professor of Dermatology and Venereology-Chairman of Sharm Derma Academy

The limited treatment options in Egypt for moderate-to-severe atopic dermatitis has left many patients and those who care for them coping with the physical and emotional burden of the disease,”. “We support timely access to this important new medication for those with moderate-to-severe atopic dermatitis to help them control and provide relief for this life-altering, often severely debilitating, chronic disease."

He added "Sometimes conventional medicine is unable to provide a radical solution to some skin diseases. The currently used therapeutic protocols only give the patient some local comfort through the use of some types of unsafe medicines for long-term use (some The types of creams or ointments that contain corticosteroids, antibiotics, and drugs that suppress the functioning of the immune system). They may cause some serious side effects such as stunted growth, weakened immune system, and other problems. For this reason, these medicines are given for periods they are limited and only in severe infections. Also, given that the genetic causes of Atopic Dermatitis are still not fully understood yet, conventional treatments may provide limited and only temporary control over the symptoms of the disease, but they are unable - unfortunately - to provide a radical solution to this disease."

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins, and is not an immunosuppressant. IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in atopic dermatitis and  asthma. 

"Globally, one out of 10 persons(11) is affected with AD  and the prevalence rate is highest in early childhood. " said Professor Dr. Mahira Hamdy El Sayed Professor of Dermatology & Venereology at Ain Shams University, Head of Egyptian Society of Dermatology. 

In Egypt, DUPIXENT is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. " "Dupixent is the only biologic medicine approved for this patient population." 

Asthma is a chronic lung disease caused by the interaction of genetic and environmental factors. It causes airways to narrow and swell and produce mucus. The main symptoms are coughing, wheezing, shortness of breath but severe asthma attacks can even lead to hospitalization. Currently, there is no cure for asthma and treatments available are used to control the symptoms (reliever) or to reduce the frequency and severity of the attacks (controller). 

"According to the WHO, asthma affected an estimated 262 million people in 2019 and caused 461000 deaths (12), said Professor Dr. Adel Khattab Professor of Pulmonary Medicine, Ain Shams University- Vice President of Egyptian Scientific Society of Bronchology.

People whose severe asthma is inadequately controlled on current therapy continue to have trouble breathing and suffer potentially life-threatening exacerbations. This daily burden and unpredictability can significantly diminish quality of life, causing missed days of school, work and social activities,"  "We, as physicians,  welcome the addition of new treatments such as Dupixent, designed to help those with severe asthma take control of their symptoms and get on with their daily lives." 

"Type 2 inflammation is responsible for many of the hallmark symptoms of asthma - and Dupixent is the first and only biological treatment approved for patients in Egypt with severe asthma characterized by multiple biomarkers of type 2 inflammation," said Professor Dr.Gihan El-Assal Professor of Pulmonary Medicine, Ain Shams University.

She added" Dupixent not only reduced exacerbations and oral corticosteroid use, but it also improved lung function and patients' overall quality of life. Dupixent offers a new treatment option for those who remain inadequately controlled with current medications, including those dependent on oral corticosteroids - which may have potentially serious side effects when used chronically." 

“At Sanofi Genzyme, is committed to delivering transformative therapies for Egyptian patients with special unmet medical needs with innovative products furthermore providing hope where there was none before. That’s why Dupixent® (dupilumab)  is considered a new hope for patients and one of the recent innovative medical treatments offered by Sanofi Genzyme for patients with moderate-to-severe Atopic Dermatitis &  severe Asthma”, said Ahmed Hegazy General Manager Sanofi Genzyme in Egypt & Sudan 

He added that Dupixent® (dupilumab)  has been successfully launched in 60 countries all over the world. Its launch in Egypt is a cornerstone for treating patients with asthma and atopic dermatitis.

-Ends-

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life 

About Sanofi Genzyme

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, rare blood disorders, neurology, immunology, and oncology. It helps people with debilitating and complex conditions that are often difficult to diagnose and treat, and is dedicated to discovering and advancing new therapies, providing hope to patients and their families worldwide. Sanofi Genzyme’s ambition is to be the industry leader in specialty care. Its approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Learn more at www.sanofigenzyme.com 

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com 

For any further information please contact :
Media Relations Contact
Mariam BISHARA
External Communication Manager
Tel.: 01099894866

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2021

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.


More From Press Releases